Los Angeles Capital Management LLC Purchases 20,801 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

by · The Cerbat Gem

Los Angeles Capital Management LLC increased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 26.3% during the 3rd quarter, Holdings Channel reports. The firm owned 100,001 shares of the company’s stock after acquiring an additional 20,801 shares during the period. Los Angeles Capital Management LLC’s holdings in Kiniksa Pharmaceuticals were worth $2,499,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of KNSA. Hhlr Advisors LTD. purchased a new stake in Kiniksa Pharmaceuticals in the 1st quarter worth $61,868,000. Vanguard Group Inc. boosted its stake in shares of Kiniksa Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock worth $58,833,000 after acquiring an additional 16,595 shares during the period. Rubric Capital Management LP grew its position in shares of Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after purchasing an additional 157,741 shares during the period. Finally, Rice Hall James & Associates LLC lifted its holdings in Kiniksa Pharmaceuticals by 8.2% in the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock worth $16,234,000 after purchasing an additional 49,000 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Stock Down 0.2 %

Kiniksa Pharmaceuticals stock opened at $22.99 on Wednesday. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $14.18 and a 52-week high of $28.15. The firm’s fifty day moving average is $24.83 and its 200 day moving average is $22.79. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -164.20 and a beta of 0.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to the consensus estimate of $111.51 million. During the same period in the previous year, the business posted ($0.20) EPS. The firm’s revenue was up 67.4% on a year-over-year basis. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $24.99, for a total transaction of $437,325.00. Following the sale, the chief operating officer now owns 116,975 shares in the company, valued at approximately $2,923,205.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, COO Eben Tessari sold 17,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $24.99, for a total transaction of $437,325.00. Following the transaction, the chief operating officer now directly owns 116,975 shares in the company, valued at approximately $2,923,205.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the sale, the insider now directly owns 52,038 shares of the company’s stock, valued at approximately $1,359,232.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 112,692 shares of company stock worth $2,950,315. 54.57% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on KNSA shares. JPMorgan Chase & Co. increased their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Wedbush increased their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Finally, Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $36.60.

View Our Latest Stock Analysis on Kiniksa Pharmaceuticals

About Kiniksa Pharmaceuticals

(Free Report)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Featured Stories

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report).